Overview

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Status:
Recruiting
Trial end date:
2022-08-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Celgene